Benzothiazoline compounds

SUMMARY OF THE INVENTION
This invention relates to benzothiazoline derivatives of the formula [I] and salts thereof, ##STR3## wherein
R.sup.1 is lower alkanoyl;
R.sup.2 is one or more group(s) selected from hydrogen, lower alkyl, lower alkoxy, hydroxy, halogen, nitro, halogenolower alkyl and sulfamoyl;
R.sup.3 is ##STR4## or --COR.sup.8 ;
R.sup.4 and R.sup.5, which may be same or different, each is hydrogen, lower alkyl, cyclohexyl or substituted lower alkyl wherein the substituent(s) is/are selected from the group consisting of hydroxy, phenyl, pyridyl, piperidyl or phenylcarbonyl, and said phenyl nucleus may be resubstituted by one or more groups selected from lower alkyl, hydroxy, halogen, lower alkoxy, nitro, cyano, acetamino and lower alkylamino;
R.sup.6 is hydrogen, alkyl containing 1 to 8 carbon atoms, alkanoyl containing 2 to 8 carbon atoms, alkenoyl containing 2 to 8 carbon atoms or furylcarbonyl, each of which alkyl, alkanoyl and alkenoyl may be substituted by one or more groups selected from hydroxy, phenyl and phenylcarbonyloxy, and said phenyl nucleus may be resubstituted by one or more groups selected from lower alkyl, hydroxy, halogen, lower alkoxy, nitro, cyano, acetamino and lower-alkylamino;
R.sup.7 is hydrogen, hydroxy, phenyl-lower alkyl or benzoyl;
R.sup.8 is hydroxy, lower alkoxy, ##STR5##
Z is straight or branched alkylene containing 1 to 6 carbon atoms;
m is 0 or 1;
n is 0 or 1;
p is 4 or 5,
wherein the terms lower alkyl, lower alkoxy and lower alkanoyl refer to groups having 1 to 6 carbon atoms.
The same shall be applied hereinafter.
BACKGROUND OF THE INVENTION
The compounds of this invention are novel benzothiazoline derivatives wherein the substituent at 3-position on the benzothiazoline ring is lower alkanoyl and that at 2-position is phenyl which is resubstituted by ether group at any position. 2-Phenylbenzothiazoline derivatives were reported by H. Breuer et al. (U.S. Pat. No. 3,720,683), H. D. Cossey et al. (J. Chem. Soc., 1965, 954) and P. J. Palmer et al. (J. Med. Chem., 14, 248). The U.S. Pat. of Breuer et al. relates to 2-phenylbenzothiazoline derivatives in which phenyl nucleus is substituted by alkyl, etc. but not ether group, and the pharmacological effects are for anti-inflammatory and anti-microbiral. Cossey et al. and Palmer et al. reported 2-phenylbenzothiazoline derivatives in which phenyl nucleus is substituted by ether group, but the substituent of 3-position is not lower alkanoyl but hydrogen, alkyl, benzyl, etc., and the pharmacological effect is for anti-microbiral.
DETAILED DESCRIPTION OF THE INVENTION
This invention relates to benzothiazoline derivatives of the formula [I]. ##STR6##
The compounds of this invention are benzothiazoline derivatives wherein the substituent at 3-position on the benzothiazoline ring is lower alkanoyl and that at 2-position is phenyl which is resubstituted by ether group at any position. The compounds of this invention are not only new in chemical structure but also found useful for treatment of cardiovascular diseases and such effect on cardiovascular diseases has not been found in the known benzothiazoline derivatives. Cardiovascular diseases are angina cordis, arrhythmia, thrombosis, etc., and .beta.-blocker, inhibitor of platelet aggregation, calcium antagonist, etc. are used as therapeutic agent. From the pharmacological tests, it is proved that the compounds of this invention possess a superior platelet anti-aggregation effect and calcium antagonization, so they are useful for cardiovascular diseases. Processes for preparing the compounds of this invention are summarized as follows. The reaction of the compound of the formula [II] with the compound of the formula [III], ##STR7##
wherein X is halogen (the same shall be applied hereinafter), or the reaction reversed the above reaction order, i.e., the reaction of the compound of the formula [IV] with the amine derivative, ##STR8## wherein
Y is halogen, carboxy or formyl, and Y and --OH may be jointed to form epoxy ring;
Amine derivative is ##STR9##
q is 0 or 1,
the same shall be applied hereinafter. The processes are explained in detail as follows. The reaction of the hydroxy derivative of the formula [II] with the halide of the formula [III] needs no specific conditions, and known methods which are generally used for a reaction of hydroxy derivative with halide can be employed, but preferably the reaction is carried out in organic solvent (for example, dimethylformamide) in the presence of base (for example, NaH). The reaction of the compound of the formula [IV] with amine derivative is divided into the following (a)-(d) reactions. ##STR10## Specific conditions are unnecessary for the above-mentioned reactions. Methods which are generally used for a reaction of amine derivative with halide, carboxylic acid derivative, aldehyde derivative or epoxy derivative can be employed.
The compounds of this invention can be converted to acid salts. Said salts are obtained by general methods using inorganic acids or organic acids. Examples of pharmaceutically acceptable salts of the compounds are hydrochloride salt, sulfuric acid salt, phosphoric acid salt, lactic acid salt, maleic acid salt, fumaric acid salt, methanesulfonic acid salt, p-toluenesulfonic acid salt, oxalic acid salt, etc.
The compounds of the formula [I] have stereoisomers because of the existence of one or more asymmetric carbon atoms, and these isomers are included in this invention.
Examples are shown below, and the compounds of this invention are listed in Table I-IX.
The assignments of the NMR spectra in Table X are made according to the numbers of the formula [IX]. ##STR11## But, protons (aromatic), not be assigned, are named as aromatic H (Ar--H). Proton of --OCH.sub.3 group is assigned as --OCHHD 3(P) when the group is attached to C.sub.2 '-C.sub.6 ' position of the formula [IX], and assigned as --OCHHD 3(A) when the group is attached to the phenyl group which is the substituent of amine moeity of the side chain.

EXAMPLE 1
3-Acetyl-2-[2-(3-t-butylamino-2-hydroxypropoxy)phenyl]benzothiazoline hydrochloride (Compound No. 86)
1.31 g of 3-acetyl-2-[2-(2,3-epoxypropoxy)phenyl]benzothiazoline and 4.21 ml of t-butylamine are dissolved in 10 ml of ethanol and the solution is refluxed for 1 hour. After cooling, 2 ml of 2N HCl/ethyl acetate is added to the reaction mixture and the solution is concentrated in vacuo. To the residue ether is added to produce crystals. Crystals are collected by filtration to give 1.3 g (81%) of the titled compound.
Physical data are shown in Table VII.
The compounds shown in Table VII are prepared by the similar method descrived above using corresponding amine derivatives.
EXAMPLE 2
3-Acetyl-2-[2-(3-t-butylamino-2-hydroxypropoxy)phenyl]benzothiazoline hydrochloride (Compound No. 86)
1.64 g of 3-acetyl-2-[2-(2,3-epoxypropoxy)phenyl]benzothiazoline, 1.82 g of 3-acetyl-2-[2-(3-chloro-2-hydroxypropoxy)phenyl]benzothiazoline and 10 ml of t-butylamine are dissolved in 30 ml of ethanol and the solution is refluxed for 3 hours. The solution is concentrated in vacuo, and the residue is dissolved in ethyl acetate. The solution is washed with saturated sodium chloride solution and dried over anhydrous magnesium sulfate. To this solution 2N HCl/ether is added to produce crystals. Crystals are filtered to give 3.5 g (80%) of the titled compound.
The physical constant of the crystals is the same of the compound obtained in Example 1.
EXAMPLE 3
3-Acetyl-2-[2-(3-dimethylaminopropoxy)phenyl]benzothiazoline (Compound No. 7)
To the suspension of 0.26 g of sodium hydride in anhydrous DMF, the soution of 1.36 g of 3-acetyl-2-(2-hydroxyphenyl)-benzothiazoline in 5 ml of anhydrous DMF is added dropwise under nitrogen atmosphere at room temperature. After the addition, the reaction mixture is stirred for 20 minutes at room temperature. To the reaction mixture, the solution of 0.61 g of 3-dimethylaminopropyl chloride in 10 ml of anhydrous DMF is added. The reaction mixture is stirred for 2 hours at 80.degree. C., and washed with n-hexane after cooling and poured into ice-water. The separated oil is extracted with ethyl acetate. The organic layer is washed with N--NaOH solution, water and saturated sodium chloride solution in the order named and dried over anhydrous magnesium sulfate. Ethy acetate is removed off in vacuo to give 1.0 g (56%) of the titled compound.
Physical data are shown in Table I.
The compounds shown in Table I, II and III are prepared by the similar method described above using corresponding benzothiazoline derivatives and substituted aminoalkyl halides.
EXAMPLE 4
3-Acetyl-2-[2-(3-aminopropoxy)phenyl]benzothiazoline hydrochloride (Compound No. 1)
By substituting 0.83 g of 3-aminopropyl bromide for 3-dimetylaminopropyl chloride in the procedure of Example 3, 1.2 g of the titled compound is obtained.
Physical data are shown in Table I.
EXAMPLE 5
3-Acetyl-2-[2-(3-diethylaminopropoxy)phenyl]benzothiazoline hydrochloride (Compound No. 10)
To the solution of 3.48 g of 3-acetyl-2-[2-(3-chloropropoxy)-phenyl]benzothiazoline in 20 ml of ethanol, 10.3 ml of diethylamine is added and the mixture is refluxed for 2 hours. After removal of ethanol and excess amount of diethylamine in vacuo, ethyl acetate and water are added to the residue. The organic layer is extracted with N-hydrochloric acid, the acidic layer is alkalinized with N-sodium hydroxide solution and extracted with ethyl acetate. The organic layer is washed with saturated sodium chloride solution and dried over anhydrous magnesium sulfate. The solvent is removed off in vacuo and the resulting oil is dissolved in methanol. To the solution hydrochloric acid in ethyl acetate is added to give 3.4 g (80%) of the titled compound.
Physical data are shown in Table I.
The compounds shown in Table I, II, III and VIII are prepared by the similar method described above using corresponding benzothiazoline derivatives and amine derivatives.
EXAMPLE 6
3-Acetyl-2-[2-(3-methylaminopropoxy)phenyl]benzothiazoline fumarate (Compound No. 2)
To the solution of 6.55 g of 3-acetyl-2-[2-(3-oxopropoxy)-phenyl]benzothiazoline in 100 ml of methanol, 8.10 g of methylamine hydrochloride and 10.0 g of molecular sieves(3A), smashed into fine pieces, are added. To the suspension 1.26 g of sodium cyano borohydride is added and the mixture is stirred for 1 hour at room temperature. 2N-Hydrochloric acid is added to the reaction mixture and methanol is removed off in vacuo. The aqueous layer is washed with ethyl acetate and alkalinized with 2N-sodium hydroxide solution and extracted with ethyl acetate. The organic layer is washed with saturated sodium chloride solution and dried over anhydrous magnesium sulfate. The solvent is removed off in vacuo and the resulting oil is dissolved in methanol. To the solution fumaric acid and ethyl acetate are added to give 4.9 g (65%) of the titled compound.
Physical data are shown in Table I.
EXAMPLE 7
3-Acetyl-2-[2-[5-(N-cyclohexyl-N-methlamino)pentyloxy]-5-methoxyphenyl]benzothiazoline fumarate (Compound No. 21)
By substituting 4.50 g of 3-acetyl-2-[2-(5-bromopentyloxy)-5-methoxyphenyl]benzothiazoline for 3-acetyl-2-[2-(3-chloropropoxy)phenyl]benzothiazoline and 3.40 g of N-methylcyclohexylamine for diethylamine in the procedure of Example 5, 4.2 g (70%) of the titled compound is obtained.
Physical data are shown in Table I.
The compounds shown in Table I are prepared by the similar method described above using corresponding benzothiazoline derivatives and amine derivatives.
EXAMPLE 8
3-Acetyl-2-[3-[3-(N-cyclohexyl-N-methylamino)propoxy]-4-hydroxyphenyl]benzothiazoline fumarate (Compound No. 37)
3.64 g of 3-acetyl-2-[3-(3-chloropropoxy)-4-hydroxyphenyl]-benzothiazoline and 3.40 g of N-methylcyclohexylamine are stirred at 100.degree. C. for 1 hour. After cooling to room temperature, the reaction mixture is dissolved in 50 ml of chloroform, the solution is washed with N-hydrochloric acid, N-sodium hydroxide solution and saturated sodium chloride solution in the named order and dried over anhydrous magnesium sulfate. Chloroform is removed off in vacuo and the residue is purified by silica gel column chromatography. The oily product is dissolved in 20 ml of ethyl acetate. To the solution 0.71 g of fumaric acid in 3 ml of methanol is added to give 2.7 g (50%) of the titled compound.
Physical data are shown in Table II.
The compounds shown in Table II and III are prepared by the similar method described above using corresponding benzothiazoline derivatives and amine derivatives.
EXAMPLE 9
3-Acetyl-2-[2-[2-[4-(3,4-dimethoxyphenetyl)-1-piperazinyl]ethoxy]-phenyl]benzothiazoline dimaleate (Compound No. 57)
3.34 g of 3-acetyl-2-[2-(2-chloroethoxy)phenyl]benzothiazoline and 5.01 g of 1-(3,4-dimethoxyphenetyl)piperazine are stirred at 110.degree. C. for 1 hour. After cooling to room temperature, the reaction mixture is dissolved in 50 ml of chloroform, the solution is washed with N-hydrochloric acid, N-sodium hydroxide solution and saturated sodium chloride solution in the named order and dried over anhydrous magnesium sulfate. Chloroform is removed off in vacuo and the resulting oil is dissolved in 50 ml of ethyl acetate. To the solution 2.32 g of maleic acid in 30 ml of ethyl acetate is added to give 6.24 g (80%) of the titled compound.
Physical data are shown in Table IV.
The compounds shown in Table I, IV, V, VI and VIII are prepared by the similar method described above using corresponding benzothiazoline derivatives and amine derivatives.
EXAMPLE 10
3-Acetyl-2-[2-[3-(ethoxycarbonyl)propoxy]phenyl]benzothiazoline (Compound No. 97)
To the suspension of 1.59 g of sodium hydride in 30 ml of anhydrous DMF, the solution of 8.13 g of 3-acetyl-2-(2-hydroxyphenyl)benzothiazoline in 30 ml of anhydrous DMF is added dropwise under nitrogen atmosphere at room temperature. After the addition, the reaction mixture is stirred for 20 minutes at room temperature. To the reaction mixture, the solution of 4.95 g of ethyl 4-chlorobutyrate in 15 ml of anhydrous DMF is added and stirred for 5 hours at 70.degree. C. After cooling to room temperature the reaction mixture is poured into ice-water and extracted with ethyl acetate.
The organic layer is washed with N-potassium hydroxide solution, water, N-hydrochloric acid and saturated sodium chloride solution in the named order and dried over anhydrous magnesium sulfate. The solvent is removed off and the resulting oil is purified by silica gel column chromatography to give 8.67 g (75%) of the titled compound.
Physical data are shown in Table IX.
EXAMPLE 11
3-Acetyl-2-[2-[3-(carboxy)propoxy]phenyl]benzothiazoline (Compound No. 96)
To the solution of 7.71 g of 3-acetyl-2-[2-[3-(ethoxycarbonyl)-propoxy]phenyl]benzothiazoline in 50 ml of methanol, 2N-sodium hydroxide solution is added and the reaction mixture is stirred for 2 hours at room temperature. Methanol is removed off in vacuo. The residue is acidified with 2N-hydrochloric acid to give 5.72 g (80%) of the titled compound.
Physical data are shown in Table IX.
EXAMPLE 12
3-Acetyl-2-[2-[3-(morpholinocarbonyl)propoxy]phenyl]benzothiazoline (Compound No. 100)
To the solution of 1.79 g of 3-acetyl-2-[2-[3-(carboxy)-propoxy]phenyl]benzothiazoline and 0.51 g of triethylamine in 20 ml of anhydrous methylene chloride, 0.68 g of isobutyl chloroformate is added dropwise while stirring at -13.degree. C. and stirred additional 10 minutes at the same temperature. To the solution 0.44 g of morpholine in 5 ml of methylene chloride is added dropwise.
After the addition, the reaction mixture is stirred for 1 hour under ice-water cooling and for 1 hour at room temperature. The reaction mixture is washed with 5% citric acid solution, water, N-potassium hydroxide solution and saturated sodium chloride solution in the named oder and dried over anhydrous magnesium sulfate. The solvent is removed off in vacuo to give 1.60 g (75%) of the titled compound.
Physical data are shown in Table IX.
The compounds shown in Table IX are prepared by the similar method described above using corresponding amine derivatives.
TABLE I__________________________________________________________________________ ##STR12## Method of prepn. mp (.degree.C.)Compd. (Examp. Yield (Recrystn.No. R.sup.2 R.sup.4 R.sup.5 r No.) (%) solvent) IR(KBr,__________________________________________________________________________ cm.sup.-1) 1*.sup.1 H H H 3 4 65 106-109(dec.) 3400, 1660, 1466, 1382, 1232, 748 2*.sup.2 H H CH.sub.3 3 6 65 111-113 3420, 1674, 1458, 1370, 724, 616 3*.sup.1 H H C(CH.sub.3).sub.3 4 5 75 193-195 3500, 3430, 2950, 2770, 1667, 1585, 1455, 1371, 1320, 1266, 1221, 1095, 741 4*.sup.1 H H ##STR13## 3 5 75 235.5-238.0 (dec.) 3020, 2940, 1678, 1598, 1488, 1462 1376, 1244, 1226, 1098, 744 5*.sup.1 H H ##STR14## 3 5 70 165-169 3420, 2940, 1676, 1514, 1462, 1378, 1324, 1262, 1250, 1288, 1022, 746 6*.sup.1 H CH.sub.3 CH.sub.3 2 3 80 209-210 3430, 1670, 1460, (MeOHAcOEt) 1387, 1354, 1325, 1272, 1245, 1230, 1170, 1103, 1050, 1022, 930, 750 7 H CH.sub.3 CH.sub.3 3 3 56 92.5-94.5 1678, 1600, 1466, ((Me.sub.2 CH).sub.2 O 1376, 1312, 1274, hexane) 1246, 1218, 1006, 746 8*.sup.1 H CH.sub.3 ##STR15## 3 5 75 130-142 (MeOHAcOEt) 3400, 2930, 2910, 1672, 1464, 1380, 1322, 1272, 1242, 1224, 750 9*.sup.3 H CH.sub.3 CH.sub.2 Ph 3 5 80 159-162 3450, 1676, 1580, 1490, 1466, 1380, 750, 70210*.sup.1 H CH.sub.2 CH.sub.3 CH.sub.2 CH.sub.3 3 5 80 154-156 3480, 3420, 2930, (MeOHAcOEt) 1676, 1462, 1378, 1320, 1270, 1240, 1224, 1098, 75211*.sup.1 H CH.sub.2 CH.sub.3 CH.sub. 2 CH.sub.3 4 5 80 amorph. 3420, 1665, 1465, 1380, 1324, 1270, 1230, 74812*.sup.1 H ##STR16## ##STR17## 3 5 65 amorph. 2940, 2870, 1684, 1468, 1380, 750 13*.sup.1 H CH.sub.2 CH.sub.2 OH CH.sub.2 CH.sub.2 OH 3 9 60 145-149 3320, 1666, 1466, 1380, 1314, 1236, 74814*.sup.1 3-OCH.sub.3 CH.sub.3 CH.sub.3 3 3 70 221-222 3410, 1665, 1580, (MeOH) 1465, 1375, 1343, 1270, 1232, 1060, 1030, 753, 74015*.sup.1 3-OCH.sub.3 CH.sub.3 CH.sub.3 4 5 65 199-200 3420, 2930, 1675, 1575, 1460, 1375, 1268, 753, 740 16*.sup.3 3-OCH.sub.3 CH.sub.3 ##STR18## 3 5 70 amorph. 3400, 2930, 1710, 1665, 1575, 1460, 1370, 1268, 1055, 745 17*.sup.1 3-OCH.sub.3 CH.sub.3 ##STR19## 4 5 60 197-198 3550, 3460, 2950, 1675, 1660, 1482, 1466, 1380, 1272, 1055, 775, 750 18*.sup.3 5-OCH.sub.3 CH.sub.3 CH.sub.3 3 3 73 165.5-166 3430, 1672, 1580, (MeOH) 1492, 1465, 1373, 1207, 1053, 870, 749 19*.sup.4 5-OCH.sub.3 CH.sub.3 ##STR20## 3 5 80 191.5-192 (dec.) (CH.sub.3 CNMeOH) 3420, 3180, 2860, 1769, 1670, 1498, 1460, 1380, 1368, 1300, 1280, 1209, 1060, 750, 715 20*.sup.4 5-OCH.sub.3 CH.sub.3 ##STR21## 4 5 60 147-148 (CH.sub.3 CN) 3420, 1670, 1493, 1463, 1372, 1275, 1240, 1208, 1037, 743, 720 21*.sup.2 5-OCH.sub.3 CH.sub.3 ##STR22## 5 7 70 155.5-157.5 3420, 2930, 1670, 1466, 1380, 1275, 1207 22*.sup.4 5-OCH.sub.3 CH.sub.3 ##STR23## 6 7 55 135-137 3440, 1675, 1493, 1465, 1380, 1280, 1210, 1040, 750, 720, 700 23*.sup.1 5-OCH.sub.3 CH.sub.3 ##STR24## 4 9 80 amorph. 3424, 1664, 1493, 1463, 1377, 1321, 1272, 1262, 1236, 1208, 1155, 1028 748 24*.sup.1 5-OCH.sub.3 ##STR25## CH.sub.2 CH.sub.2 OH 4 9 70 amorph. 3336, 1664, 1493, 1464, 1397, 1274, 1208, 1036, 748 25*.sup.1 5-OCH.sub.3 ##STR26## ##STR27## 4 9 75 amorph. 3424, 1668, 1510, 1496, 1466, 1272, 1262, 1237, 1208, 1025, 750 26*.sup.1 5-Cl CH.sub.3 CH.sub.3 3 3 70 193-195.5 3420, 1678, 1466, ((Me.sub.2 CH).sub.2 OEt.sub.2 O) 1376, 1226, 1110, 1035, 764 27*.sup.1 3-NO.sub.2 CH.sub.3 ##STR28## 3 5 70 103-106 3420, 1668, 1598,1528, 1464, 1376,1348, 1319, 1270,1225, 742 28*.sup.2 5-NO.sub.2 CH.sub.3 CH.sub.3 3 3 65 159-160 (dec.) 3420, 1670, 1610 (MeOHCH.sub.3 CN 1591, 1515, 1463, 1379, 1340, 1268, 1225, 1078, 1032, 980, 745 29*.sup.2 5-NO.sub.2 CH.sub.3 ##STR29## 3 5 55 168-169 (dec.)(MeOHCH.sub.3 CN) 3460, 1693, 1670,1588, 1512, 1461,1375, 1336, 1265,1212, 1074, 741 30*.sup.2 5-NO.sub.2 CH.sub.3 ##STR30## 4 5 60 176.5-178 (dec.)(MeOHCH.sub.3 CN) 3420, 1695, 1591,1510, 1465, 1379,1341, 1267, 1226,1079, 755 31*.sup.2 5-NO.sub.2 CH.sub.3 ##STR31## 5 7 70 172-174 (dec.)(MeOHCH.sub.3 CN) 3430, 1710, 1675,1591, 1511, 1467,1380, 1336, 1265,1230, 1078, 982,747 32*.sup.2 5-NO.sub.2 CH.sub.3 ##STR32## 6 7 70 178-180 (dec.)(MeOHCH.sub.3 CN) 3430, 1715, 1679,1591, 1511, 1461,1377, 1335, 1268,1227, 1077, 982,749 33*.sup.5 5-NO.sub.2 H ##STR33## 3 9 55 83-85(AcOEt) 3400, 3290, 1678,1612, 1592, 1580,1522, 1466, 1348,1338, 1268, 1080,748 34*.sup.2 3OCH.sub.35-NO.sub.2 CH.sub.3 ##STR34## 3 5 65 157-159(MeOHCH.sub.3 CN) 3420, 1705, 1677,1570, 1530, 1463,1370, 1340, 1294,1273, 1213, 11941162, 1062, 981,63,__________________________________________________________________________ 738 *.sup.1 Hydrochloride *.sup.2 Fumarate *.sup.3 Maleate *.sup.4 Oxalate *.sup.5 Monohydrate
TABLE II__________________________________________________________________________ ##STR35## Method of mp(.degree.C.)Compd. prepn. Yield (Recrystn.No. R.sup.2 R.sup.4 R.sup.5 r (Examp. No.) (%) solvent) IR(KBr, cm.sup.-1)__________________________________________________________________________35*.sup.1 H CH.sub.3 CH.sub.3 3 3 70 162-164 3420, 1716, 1680, 1606, 1586, 1463, 1381, 1306, 1288, 95436 4-OH CH.sub.3 CH.sub.3 3 8 30 oil 3340, 1675, 1585, 1510, 1480, 1430, 1300, 1270, 1141, 750 (neat)37*.sup.1 4-OH CH.sub.3 ##STR36## 3 8 50 130-133 (dec.) 3400, 1670, 1575, 1510, 1462, 1430, 1375, 1340, 1320, 1272, 1230, 1208, 985, 745 38*.sup.2 4-OCH.sub.3 CH.sub.3 ##STR37## 4 5 85 amorph. 3400, 1660, 1512, 1460, 1380, 1340, 1255, 1135, 1020, 750 39*.sup.2 4-NO.sub.2 CH.sub.3 ##STR38## 3 5 70 115-117 3420, 1662, 1606, 1513, 1464, 1375, 1343, 1314, 1272, 745 40*.sup.2 6-NO.sub.2 CH.sub.3 ##STR39## 3 5 65 69-73 3430, 1665, 1610, 1580, 1510, 1468, 1378, 1318, 1290, 1226,__________________________________________________________________________ 748 *.sup.1 Fumarate *.sup.2 Hydrochloride
TABLE III__________________________________________________________________________ ##STR40## Method of mp(.degree.C.)Compd. prepn. Yield (Recrystn.No. R.sup.2 R.sup.4 R.sup.5 r (Examp. No.) (%) solvent) IR(KBr, cm.sup.-1)__________________________________________________________________________41*.sup.1 H CH.sub.3 CH.sub.3 2 3 80 amorph. 3410, 1664, 1510, 1464, 1378, 1234, 74842*.sup.1 H CH.sub.3 CH.sub.3 3 3 75 oil 3400, 1660, 1610, 1580, 1460, 1380, 1230, 1174, 750 (neat)43*.sup.1 H CH.sub.3 CH.sub.3 4 5 80 amorph. 3420, 2940, 1666, 1510, 1464, 1376, 1244, 1174, 748 44*.sup.1 H CH.sub.3 ##STR41## 3 5 75 amorph. 3420, 2940, 1684, 1510, 1462, 1376, 1326, 1268, 1244, 1230, 1174, 748 45*.sup.1 H CH.sub.3 ##STR42## 4 5 75 amorph. 3420, 2940, 1666, 1510, 1464, 1376, 1328, 1270, 1244, 1174, 748 46*.sup.1 H CH.sub.2 CH.sub.3 CH.sub.2 CH.sub.3 3 5 75 amorph. 3420, 2930, 1662, 1506, 1460, 1374, 1324, 1266, 1238, 1172, 748 47 .sup. 3-OH CH.sub.3 ##STR43## 3 8 40 oil 3330, 1666, 1575, 1502, 1461, 1376, 1340, 1270, 1216, 1121, 1025, 745 (neat) 48*.sup.1 3-OCH.sub.3 CH.sub.3 CH.sub.3 3 3 80 amorph. 3420, 1662, 1510, 1460, 1375, 1335, 1256, 1230, 1132, 1025, 74649*.sup.1 3-OCH.sub.3 CH.sub.3 CH.sub.3 4 5 70 amorph. 3420, 1665, 1510, 1462, 1375, 1255, 1230, 1132, 1025, 750 50*.sup.1 3-OCH.sub.3 CH.sub.3 ##STR44## 3 5 75 amorph. 3420, 1666, 1512, 1465, 1378, 1255, 1230, 1135, 1027, 750 51*.sup.1 3-OCH.sub.3 CH.sub.3 ##STR45## 4 5 70 amorph. 3400, 1663, 1510, 1460, 1378, 1255, 1132, 1025, 746 52*.sup.1 3-NO.sub.2 CH.sub.3 ##STR46## 3 5 75 amorph. 3420, 1665, 1618, 1530, 1463, 1376, 1350, 1320, 1270, 1081, 1027, 749 53*.sup.1 3-OCH.sub.3 CH.sub.3 CH.sub.3 3 5 65 amorph. 3410, 2940, 1656, 1582, 1452, 5-OCH.sub.3 1412, 1368, 1318, 1220, 1112, 740 54*.sup.1 3-OCH.sub.3 5-OCH.sub.3 CH.sub.3 ##STR47## 3 5 60 amorph. 3440, 2950, 1664, 1588, 1462, 1420, 1380, 1338, 1236, 1124, 752 55*.sup.1 3-OCH.sub.3 5-OCH.sub.3 CH.sub.3 ##STR48## 4 5 75 amorph. 3420, 2932, 1664, 1589, 1458, 1419, 1379, 1327, 1271, 1229, 1122__________________________________________________________________________ *.sup.1 Hydrochloride
TABLE IV__________________________________________________________________________ ##STR49## Method of mp(.degree.C.)Compd. prepn. Yield (Recrystn.No. R.sup.2 R.sup.6 r (Examp. No.) (%) solvent) IR(KBr,__________________________________________________________________________ cm.sup.-1)56*.sup.1 H CH.sub.3 3 3 65 213-215 3400, 1664, 1460, 1376, 1322, 1272, 1226, 746 57*.sup.2 H ##STR50## 2 9 80 181-182 (dec.) (MeOHCH.sub.3 CN) 3430, 1683, 1615, 1573, 1513, 1460, 1375, 1352, 1319, 1259, 1222, 1095, 1022, 860, 755 58*.sup.2 H ##STR51## 3 9 70 172-173 (dec.) (MeOHCH.sub.3 CN) 3430, 1687, 1619, 1570, 1515, 1460, 1378, 1352, 1321, 1260, 1238, 1225, 1098, 1024, 864, 755, 43 59*.sup.3 H ##STR52## 2 9 60 144-146 (dec.) (MeOHCH.sub.3 CN) 3420, 1705, 1682, 1651, 1586, 1511, 1459, 1374, 1263, 1223, 1152, 1022, 751 60*.sup.3 H ##STR53## 3 9 75 149-151 (dec.) (CH.sub.3 3420, 1712, 1679, 1647, 1590, 1513, 1460, 1375, 1262, 1227, 1155, 1023, 975, 750 61*.sup.4 H ##STR54## 3 9 85 131-132 (dec.) (MeOHEt.sub.2 3420, 1670, 1640, 1585, 1512, 1459, 1374, 1260, 1138, 1022, 740 62*.sup.2 5-OCH.sub.3 ##STR55## 3 9 60 181-182 (dec.) (MeOHCH.sub.3 CN) 3430, 1671, 1618, 1572, 1492, 1462, 1377, 1353, 1322, 1260, 1236, 1207, 1155, 1099, 1025, 862, 745 63*.sup.5 5-OCH.sub.3 ##STR56## 4 9 65 197.5-198.5 (MeOHCH.sub.3 3420, 1708, 1668, 1575, 1495, 1461, 1373, 1295, 1267, 1233, 1205, 1152, 1022, 973, 743 64*.sup.2 5-OCH.sub.3 ##STR57## 5 9 70 195.5-197.5 (dec.) 3440, 1664, 1580, 1500, 1466, 1381, 1208, 1023, 865 65*.sup.2 5-OCH.sub.3 ##STR58## 6 9 80 188-189 (MeOHCH.sub.3 CN) 3430, 1670, 1618, 1570, 1465, 1380, 1354, 1260, 1240, 1210, 1027, 865 66*.sup.2 5-OCH.sub.3 CH.sub.2 CH.sub.2 CH 4 9 80 186-187 (dec.) (MeOHCH.sub.3 CN) 3480, 1700, 1672, 1620, 1575, 1490, 1468, 1380, 1359, 1276, 1210, 1070, 865, 746 67*.sup.1 5-OCH.sub.3 ##STR59## 4 9 80 239-240 (dec. 3420, 1674, 1588, 1500, 1460, 1420, 1376, 1232, 1212, 1120, 1040, 758 68*.sup.2 5-OCH.sub.3 ##STR60## 4 9 80 175-177 (EtOHCH.sub.3 CN) 3430, 1664, 1571, 1492, 1465, 1379, 1360, 1277, 1208, 1102, 1062, 864 69*.sup.5 5-OCH.sub.3 ##STR61## 4 9 70 170-173 3440, 1491, 1465, 1379, 1274, 1209, 752 70*.sup.2 5-OCH.sub.3 ##STR62## 4 9 75 181-182.5 (dec.) (MeOHCH.sub.3 CN) 3450, 1710, 1672, 1580, 1466, 1378, 1355, 1330, 1210, 1123, 862, 74671*.sup.3 5-OCH.sub.3 ##STR63## 3 9 65 130-131 (dec.) (AcOEt) 3420, 1701, 1660, 1641, 1590, 1515, 1499, 1463, 1372, 1272, 1260, 1231, 1207, 1140, 1023, 980, 750 72*.sup.6 5-OCH.sub.3 ##STR64## 3 9 70 175-176 (dec.) (MeOHCH.sub.3 CN) 3430, 1641, 1580, 1509, 1462, 1373, 1260, 1207, 1136, 1022, 975, 863, 74573*.sup.2 5-NO.sub.2 (CH.sub.2).sub.7 CH.sub.3 3 9 75 176.5-177.5 3420, 1676, 1610, 1580, (MeOHCH.sub.3 CN) 1510, 1468, 1380, 1342, 1272, 1080, 865, 748 74*.sup.2 5-NO.sub.2 ##STR65## 3 9 90 156.5-1158 (dec.) (MeOHCH.sub.3 CN) 3420, 1660, 1573, 1508, 1461, 1378, 1262, 1020, 860, 741, 710 75*.sup.7 5-NO.sub.2 CO(CH.sub.2).sub.6 CH.sub.3 3 9 70 90-92.5 3450, 1650, 1590, 1466, (CHCl.sub.3Et.sub.2 O) 1340, 1270, 748, 712 76*.sup.2 5-NO.sub.2 ##STR66## 3 9 75 144-145 (dec.) 3410, 1661, 1572, 1508, 1462, 1378, 1337, 1267, 1225, 1074, 1011, 860, 741 77*.sup.2 5-NO.sub.2 ##STR67## 3 9 70 153-155 (dec.) (EtOH) 3392, 1654, 1576, 1508, 1465, 1381, 1340, 1270, 1192, 1077, 1013, 863, 745, 701 78*.sup.8 H ##STR68## 3 9 75 199-202 (dec.) (DMSOH.sub.2 3400, 1663, 1647, 1597, 1510, 1463, 1398, 1380, 1339, 1271, 1225, 1168, 718 79*.sup.4 5-NO.sub.2 ##STR69## 3 9 80 181-183 (MeOHCH.sub.3 CN) 3492, 3400, 1671, 1618, 1593,1513, 1484, 1466, 1384, 1339, 1273, 1229, 1080, 759, 742 80*.sup.1 3-OCH.sub.3 5-NO.sub.2 ##STR70## 3 9 75 147-150 (dec.) (MeOHH.sub.2 3410, 1662, 1514, 1460, 1374, 1338, 1291, 1236, 1139, 1098, 1060, 1021, 951,__________________________________________________________________________ 747 *.sup.1 Dihydrochloride *.sup.2 Dimaleate *.sup.3 Fumarate *.sup.4 Hydrochloride *.sup.5 Difumarate *.sup.6 Maleate *.sup.7 Oxalate *.sup. 8 Dioxalate
TABLE V__________________________________________________________________________ ##STR71## Method of mp(.degree.C.)Compd. prepn. Yield (Recrystn.No. R.sup.2 R.sup.6 r (Examp. No.) (%) solvent) IR(KBr,__________________________________________________________________________ cm.sup.-1)81* 4-OCH.sub.3 ##STR72## 4 9 85 168-169 (MeOHCH.sub.3 CN) 3450, 1682, 1620, 1580, 1515, 1460, 1375, 1359, 1336, 1260, 1240, 1139, 1027, 865,__________________________________________________________________________ 745 *Dimalate
TABLE VI__________________________________________________________________________ ##STR73## Method of mp(.degree.C.)Compd. prepn. Yield (Recrystn.No. R.sup.2 R.sup.6 r (Examp. No.) (%) solvent) IR(KBr, cm.sup.-1)__________________________________________________________________________82*.sup.1 H ##STR74## 3 9 60 175-177 (dec.) (MeOHCH.sub.3 3420, 1712, 1660, 1575, 1509, 1462, 1373, 1300, 1260, 1233, 1171, 1024, 970, 757 83*.sup.2 3-OCH.sub.3 ##STR75## 3 9 85 164-165 (MeOHCH.sub.3 CN) 3430, 1665, 1619, 1570, 1510, 1460, 1375, 1353, 1325, 1256, 1235, 1132, 1025, 865 84*.sup.2 3-OCH.sub.3 ##STR76## 4 9 80 167-168 (MeOCH.sub.3 CN) 3430, 1670, 1570, 1450, 1370, 1355, 1325, 1255, 1240, 1130, 1025, 865, 750 85*.sup.2 3-OCH.sub.3 5-OCH.sub.3 ##STR77## 4 9 70 163.5-165.5 3450, 1670, 1577, 1499, 1460, 1379, 1328, 1261, 1236, 1122, 1024,__________________________________________________________________________ 866 *.sup.1 Difumarate *.sup.2 Dimaleate
TABLE VII__________________________________________________________________________ ##STR78## Method of mp(.degree.C.)Comp. prepn. Yield (Recrystn.No. R.sup.4 R.sup.5 (Examp. No.) (%) solvent) IR(KBr, cm.sup.-1)__________________________________________________________________________86* H C(CH.sub.3).sub.3 1 81 188-192 3350, 2980, 2790, 1672, 1660, 2 (CHCl.sub.3Et.sub.2 O) 1470, 1384, 1224, 750 87a* CH.sub.3 ##STR79## 1 35 208-210 3225, 2940, 1686, 1464, 1382, 744 87b* CH.sub.3 ##STR80## 1 30 143-146 3350, 2940, 1672, 1464, 1382, 748 88* CH.sub.2 CH.sub.3 CH.sub.2 CH.sub.3 1 75 amorph. 3400, 2930, 1658, 1600, 1460, 1380, 1326, 1274, 1234, 1102, 1028, 750__________________________________________________________________________ *Hydrochloride Compound 87a is the diastereoisomer of compound 87b.
TABLE VIII__________________________________________________________________________ ##STR81## Method of mp(.degree.C.)Compd. prepn. Yield (Recrystn.No. R.sup.2 R.sup.9 r (Examp. No.) (%) solvent) IR(KBr,__________________________________________________________________________ cm.sup.-1)89*.sup.1 H ##STR82## 3 5 70 124-127 3430, 2940, 1674, 1466, 1380, 746 90 H ##STR83## 3 3 55 121-122.5 1676, 1466, 1456, 1374, 1324, 1276, 1252, 1230, 1116, 752 91*.sup.2 H ##STR84## 3 9 75 184-186 (dec.) 3450, 1728, 1685, 1605, 1465, 1384, 1280, 1254, 1238, 758 92*.sup.2 5-OCH.sub.3 ##STR85## 4 9 70 148-150 (iso-PrOH AcOEt Et.sub.2 O) 3420, 1705, 1669, 1493, 1463, 1379, 1320, 1275, 1237, 1207, 1140, 745 93*.sup.3 5-OCH.sub.3 ##STR86## 4 9 80 182-184 (MeOHCH.sub.3 CN) 3450, 1720, 1671, 1595, 1461, 1378, 1278, 1208, 702 94*.sup.3 5-NO.sub.2 ##STR87## 3 9 75 175-178 (dec.) (MeOHCH.sub.3 3408, 1664, 1610, 1592, 1509, 1459, 1381, 1340, 1270, 1226, 1074, 744, 700 95*.sup.3 5-NO.sub.2 ##STR88## 4 9 70 190-191 (dec.) (MeOHCH.sub.3 3424, 1718, 1689, 1608, 1594, 1510, 1465, 1376, 1339, 1269, 1195, 744,__________________________________________________________________________ 701 *.sup.1 Hydrochloride *.sup.2 Fumarate *.sup.3 Oxalate
TABLE IX__________________________________________________________________________ Method of mp(.degree.C.)Compd. prepn. Yield (Recrystn.No. R.sup.8 r (Examp. No.) (%) solvent) IR(KBr,__________________________________________________________________________ cm.sup.-1)96 OH 3 11 80 121-122.5 3420, 1725, 1636, 1465, 1387, (AcOEtEt.sub.2 O 1272, 1242, 1231, 1176, 1100, Me.sub.2 CHOCHMe.sub.2) 1040, 74597 OCH.sub.2 CH.sub.3 3 10 75 oil 1735, 1679, 1601, 1491, 1468, 1380, 1325, 1273, 1247, 1230, 1178, 1100, 1028, 730 (neat) 98 ##STR89## 3 12 65 amorph. 3310, 1650, 1510, 1461, 1375, 1321, 1257, 1230, 1023, 745 99* ##STR90## 3 12 80 195.5-197 (dec.) (EtOHH.sub.2 3430, 1652, 1465, 1376, 1328, 1243, 1159, 1022, 975, 747, 642 100 ##STR91## 3 12 75 133-134 (AcOEt) 1670, 1639, 1599, 1460, 1373, 1325, 1267, 1227, 1100, 1098, 1028,__________________________________________________________________________ 750 *Fumarate
X NMR No. .delta. (ppm), J = Hz 1 DMSOd.sub.6 ##STR92## OCH.sub.2), 6.60-7.40 (8H, m, C.sub.2H and ArH), 7.70-8.20 (1H, m, C.sub.4H), 8.00-8.80 (3H, br, NH.sub.2 and HCl) 2 DMSOd.sub.6 ##STR93## ##STR94## (1H, m, C.sub.4H), 9.13 (3H, br s, NHand CO.sub.2 H .times. 2) 3 DMSOd.sub.6 ##STR95## ##STR96## 9.40 (2H, br, NHand HCl) 4 DMSOd.sub.6 ##STR97## ##STR98## (1H, m, C.sub.4H), 9.50-10.53 (2H, br, NHand HCl) 5 DMSOd.sub.6 ##STR99## OCH.sub.3), 3.74 (3H, s, OCH.sub.3), 4.23 (2H, t, J = 6.0, OCH.sub.2), 6.60-7.50 (11H, m, C.sub.2H and ArH), 7.70-8.10 (1H, m, C.sub.4H), 9.50 (2H, br s, NHand HCl) 6 DMSOd.sub.6 ##STR100## 6.73-7.63 (8H, m, C.sub.2H and ArH), 7.80-8.23 (1H, m, C.sub.4H), 11.53 (1H, br s, HCl) 7 CDCl.sub.3 ##STR101## OCH.sub.2 CH.sub.2), 6.60-7.40 (8H, m, C.sub.2H and ArH), 7.70-8.30 (1H, m, C.sub.4H) 8 DMSOd.sub.6 ##STR102## ##STR103## (1H, m, C.sub.4H), 10.80-11.50 (1H, br, HCl) 9 DMSOd.sub.6 ##STR104## ##STR105## ##STR106## CO.sub.2 H .times. 2) 10 DMSOd.sub.6 ##STR107## 6H, m, CH.sub.2 N(CH.sub.2 CH.sub.3).sub.2), 4.22 (2H, t, J = 5.5, OCH.sub.2), 6.70-7.40 (8H, m, C.sub.2H and ArH), 7.70-8.10 (1H, m, C.sub.4H), 10.90-11.50 (1H, br, HCl) 11 DMSOd.sub.6 ##STR108## 3.40 (6H, m, CH.sub.2 N(CH.sub.2 CH.sub.3).sub.2), 3.90-4.33 (2H, m, O CH.sub.2), 6.60-7.57 (8H, m, C.sub.2H and ArH), 7.67-8.23 (1H, m, C.sub.4H), 10.63-11.40 (1H, br, HCl) 12 DMSOd.sub.6 ##STR109## 3.90-4.50 (2H, m, OCH.sub.2), 6.70-7.50 (8H, m, C.sub.2H) and ArH), 7.70-8.10 (1H, m, C.sub.4H), 10.10-10.60 (1H, br, HCl) 13 DMSOd.sub.6 ##STR110## (4H, m, CH.sub.2 OH .times. 2), 4.17 (2H, t, J = 5.5, OCH.sub.2), 4.50-5.20 (2H, br, OH .times. 2), 6.60-7.50 (8H, m, C.sub.2H and ArH), 7.70-8.20 (1H, m, C.sub.4H), 10.00-10.60 (1H, br, HCl) 14 DMSOd.sub.6 ##STR111## ##STR112## 7.40 (6H, m, C.sub.2H and ArH), 7.73-8.16 (1H, m, C.sub.4H), 10.50-11.73 (1H, br, HCl) 15 CDCl.sub.3 ##STR113## ##STR114## 6.70-7.30 (6H, m, C.sub.2H and ArH), 7.56-8.30 (1H, m, C.sub.4H), 11.87-12.80 (1H, br, HCl) 16 DMSOd.sub.6 ##STR115## ##STR116## 6.52 (1H, dd, J = 6.0, 3.5, C.sub.4 'H), 6.63- 7.27 (6H, m, C.sub.2H and ArH), 7.63-8.17 (1H, m, C.sub.4H), 10.00- 14.50 (2H, br, CO.sub.2 H .times. 2) 17 CDCl.sub.3 ##STR117## ##STR118## C.sub.4 'H), 6.57-7.30 (6H, m, C.sub.2H and ArH), 7.57-8.23 (1H, m, C.sub.4H), 11.40-12.23 (1H, br, HCl) 18 CDCl.sub.3 ##STR119## ##STR120## C.sub.6 'H), 6.63-7.30 (6H, m, C.sub.2H and ArH), 7.57-8.30 (1H, m, C.sub.4H), 12.65-15.50 (2H, br, CO.sub.2 H .times. 2) 19 DMSOd.sub.6 ##STR121## ##STR122## C.sub.6 'H), 6.62-7.37 (6H, m, C.sub.2H and ArH), 7.63-8.20 (1H, m, C.sub.4H), 9.82 (2H, br s, CO.sub.2 H .times. 2) 20 DMSOd.sub.6 ##STR123## ##STR124## 6.62-7.40 (6H, m, C.sub.2H and ArH), 7.70-8.20 (1H, m, C.sub.4H), 9.75 (2H, br s, CO.sub.2 H .times. 2) 21 DMSOd.sub.6 ##STR125## ##STR126## ##STR127## 22 DMSOd.sub.6 ##STR128## ##STR129## 6.63-7.40 (6H, m, C.sub.2H and ArH), 7.67-8.20 (1H, m, C.sub.4H), 9.17 (2H, br s, CO.sub.2 H .times. 2) 23 DMSOd.sub.6 ##STR130## ##STR131## 3.80-4.20 (2H, m, OCH.sub.2), 6.45 (1H, d, J = 2.0, C.sub.6 'H), 6.60-7.30 (9H, C.sub.2H and ArH), 7.70-8.10 (1H, m, C.sub.4H), 10.90-11.50 (1H, br, HCl) 24 DMSOd.sub.6 ##STR132## 3.23 (3H, s, OCH.sub.3 (P)), 3.70-4.00 (2H, m, CH.sub.2 OH), 3.90-4.30 (2H, m, OCH.sub.2), 4.67 (1H, s, OH), 6.41 (1H, d, J = 2.0, C.sub.6 'H), 6.70-7.30 (6H, m, C.sub.2H and Ar H), 7.70-8.20 (1H, m, C.sub.4H), 9.90-10.40 (1H, br, HCl) 25 DMSOd.sub.6 ##STR133## 3.57 (3H, s, OCH.sub.3 (P)), 3.65 (3H, s, OCH.sub.3 (A)), 3.71 (3H, s, OCH.sub.3 (A)), 3.90-4.30 (2H, m, OCH.sub.2), 6.42 (1H, d, J = 2.0, C.sub.6 'H), 6.60-7.20 (9H, m, C.sub.2H and ArH), 7.70-8.20 (1H, m, C.sub.4H), 10.90-11.30 (1H, br, HCl) 26 DMSOd.sub.6 ##STR134## ##STR135## m, C.sub.4H), 11.00-11.90 (1H, br, HCl) 27 CDCl.sub.3 ##STR136## ##STR137## m, C.sub.4H), 7.77 (1H, dd, J = 8.0, 2.0, C.sub.4 'H), 11.30-12.20 (1H, br, HCl) 28 DMSOd.sub.6 ##STR138## ##STR139## C.sub.7H), 7.28 (1H, d, J = 9.0, C.sub.3 'H), 7.72 (1H, d, J = 3.0, C.sub.6 'H), 7.83-8.10 (1H, m, C.sub.4H), 8.15 (1H, dd, J = 9.0, 3.0, C.sub.4 'H), 11.33 (2H, s, CO.sub.2 H .times. 2) 29 DMSOd.sub.6 ##STR140## ##STR141## C.sub. 2H, C.sub.5H, C.sub.6and C.sub.7H), 7.26 (1H, d, J = 9.0, C.sub.3 'H), 7.73 (1H, d, J = 2.5, C.sub.6 'H), 7.80-8.10 (1H, m, C.sub.4H), 8.17 (1H, dd, J = 9.0, 2.5, C.sub.4 'H), 9.65 (2H, br s, CO.sub.2 H .times. 2) 30 DMSOd.sub.6 ##STR142## ##STR143## C.sub.5H, C.sub.6H, C.sub.7H and C.sub.3 'H), 7.60-8.20 (1H, m, C.sub.4H), 7.72 (1H, d, J = 2.5, C.sub.6 'H), 8.15 (1H, dd, J = 9.0, 2.5, C.sub.4 'H), 9.73-10.52 (2H, br, CO.sub.2 H .times. 2) 31 DMSOd.sub.6 ##STR144## ##STR145## C.sub.2H, C.sub.5H, C.sub.6H, C.sub.7H and C.sub.3 'H), 7.72 (1H, d, J = 2.5, C.sub.6 'H), 7.62-8.17 (1H, m, C.sub.4H), 8.16 (1H, dd, J = 9.0, 2.5, C.sub.4 'H), 9.32-10.08 (2H, br, CO.sub.2 H .times. 2) 32 d DMSO.sub.6 ##STR146## ##STR147## C.sub.5H, C.sub.6H, C.sub.7H and C.sub.3 'H), 7.72 (1H, d, J = 2.5, C.sub.6 'H), 7.57-8.20 (1H, m, C.sub.4H), 8.18 (1H, dd, J = 9.0, 2.5, C.sub.4 'H), 9.43-10.13 (2H, br, CO.sub.2 H .times. 2) d 33 CDCl.sub.3DMSO.sub.6 ##STR148## ##STR149## 7.48-7.92 (2H, m, C.sub.4H and C.sub.3 'H), 7.78 (1H, d, J = 3.0, C.sub.6 'H), 8.12 (1H, dd, J = 9.0, 3.0, C.sub.4 'H), ##STR150## 34 DMSOd.sub.6 ##STR151## ##STR152## 6.85-7.33 (4H, m, C.sub.2H, C.sub.5H, C.sub.6H and C.sub.7H), 7.38 (1H, d, J = 2.5, C.sub.4 'H), 7.67-8.10 (1H, m, C.sub.4H), 7.78 (1H, d, J = 2.5, C.sub.6 'H), 11.05 (2H, br s, CO.sub.2 H .times. 2) 35 DMSOd.sub.6 ##STR153## ##STR154## 7.70-8.10 (1H, m, C.sub.4H), 11.44 (2H, s, CO.sub.2 H .times. 2) 36 CDCl.sub.3 ##STR155## ##STR156## 37 DMSOd.sub.6 ##STR157## ##STR158## 7.70-8.10 (1H, m, C.sub.4H), 10.00-11.37 (3H, br, CO.sub.2 H .times. 2 and OH) 38 DMSOd.sub.6 ##STR159## ##STR160## and ArH), 7.73-8.10 (1H, m, C.sub.4H), 10.47-11.07 (1H, br, HCl) 39 DMSOd.sub.6 ##STR161## ##STR162## 8.10 (1H, m, C.sub.4H), 7.78 (1H, d, J = 9.0, C.sub.5 'H), 10.71-11.32 (1H, br, HCl) 40 CDCl.sub.3DMSOd.sub.6 ##STR163## ##STR164## 8.10 (1H, m, C.sub.4H), 8.23 (1H, d, J = 9.0, C.sub.3 'H), 11.30-12.00 (1H, br, HCl) 41 DMSOd.sub.6 ##STR165## J = 5.0, OCH.sub.2), 6.90-7.40 (4H, m, C.sub.2H, C.sub.5H, C.sub.6H and C.sub.7H), 6.95 (2H, d, J = 9.0, C.sub.3 'H and C.sub.5 'H), 7.23 (2H, d, J = 9.0, C.sub.2 'H and C.sub.6 'H), 7.80-8.10 (1H, m, C.sub.4H), 10.90-11.70 (1H, br, HCl) 42 DMSOd.sub.6 ##STR166## ##STR167## 6.80 (2H, d, J = 9.0, C.sub.3 'H and C.sub.5 'H), 7.12 (2H, d, J = 9.0, C.sub.2 'H and C.sub.6 'H), 7.60-8.00 (1H, m, C.sub.4H), 11.00-11.60 (1H, br, HCl) 43 DMSOd.sub.6 ##STR168## ##STR169## 6.82 (2H, d, J = 8.5, C.sub.3 'H and C.sub.5 'H), 7.29 (2H, d, J = 8.5, C.sub.2 'H and C.sub.6 'H), 7.70-8.10 (1H, m, C.sub.4H), 10.80-11.50 (1H, br, HCl) 44 DMSOd.sub.6 ##STR170## ##STR171## 6.81 (2H, d, J = 9.0, C.sub.3 'H and C.sub.5 'H), 7.15 (2H, d, J = 9.0, C.sub.2 'H and C.sub.6 'H), 7.70-8.00 (1H, m, C.sub.4H), 10.70-11.30 (1H, br, HCl) 45 DMSOd.sub.6 ##STR172## ##STR173## 7.30 (4H, m, C.sub.2H, C.sub.5H, C.sub.6H and C.sub.7H), 7.21 (2H, d, J = 8.5, C.sub.2 'H and C.sub.6 'H), 7.70-8.10 (1H, m, C.sub.4H), 10.50-11.20 (1H, br, HCl) 46 DMSOd.sub.6 ##STR174## (6H, m, CH.sub.2 N(CH.sub.2 CH.sub.3).sub.2), 4.03 (2H, t, J = 6.0, OCH.sub.2), 6.80-7.40 (4H, m, C.sub.2H, C.sub.5H, C.sub.6H and C.sub.7H), 6.83 (2H, d, J = 8.5, C.sub.3 'H and C.sub.5 'H), 7.16 (2H, d, J = 8.5, C.sub.2 'H and C.sub.6 'H), 7.70-8.00 (1H, m, C.sub.4H), 10.70-11.30 (1H, br, HCl) 47 CDCl.sub.3 ##STR175## ##STR176## C.sub.2H and ArH), 7.57-8.10 (1H, m, C.sub.4H), 8.83-9.30 (1H, br, OH) 48 DMSOd.sub.6 ##STR177## ##STR178## 7.70-8.10 (1H, m, C.sub.4H), 10.77-11.50 (1H, br, HCl) 49 DMSOd.sub.6 ##STR179## ##STR180## 7.70-8.10 (1H, m, C.sub.4H), 10.53-11.37 (1H, br, HCl) 50 DMSOd.sub.6 ##STR181## ##STR182## ArH), 7.70-8.13 (1H, m, C.sub.4H), 10.67-11.33 (1H, br, HCl) 51 d DMSO.sub.6 ##STR183## ##STR184## C.sub.2H and ArH), 7.73-8.10 (1H, m, C.sub.4H), 10.50-11.07 (1H, br, HCl) 52 DMSOd.sub.6 ##STR185## ##STR186## (1H, m, C.sub.4H), 7.33 (1H, dd, J = 9.0, 2.5, C.sub.6 'H), 7.78 (1H, d, J = 2.5, C.sub.2 'H), 11.17-11.85 (1H, br, HCl) 53 DMSOd.sub.6 ##STR187## ##STR188## 6.98 (1H, s, C.sub.2H), 6.93-7.33 (3H, m, C.sub.5H, C.sub.6H and C.sub.7H), 7.80-8.00 (1H, m, C.sub.4H), 10.90-11.40 (1H, br, HCl) 54 DMSOd.sub.6 ##STR189## ##STR190## and C.sub.6 'H), 7.01 (1H, s, C.sub.2H), 7.00-7.40 (3H, m, C.sub.5H, C.sub.6H and C.sub.7H), 7.77-8.10 (1H, m, C.sub.4H), 10.68-11.20 (1H, br, HCl) 55 DMSOd.sub.6 ##STR191## ##STR192## C.sub.6 'H), 7.00-7.50 (4H, m, C.sub.2H, C.sub.5H, C.sub.6H and C.sub.7H), 7.80-8.10 (1H, m, C.sub.4H), 10.70-11.20 (1H, br, HCl) 56 DMSOd.sub.6 ##STR193## ##STR194## C.sub.4H), 11.20-12.50 (2H, br, HCl .times. 2) 57 DMSOd.sub.6 ##STR195## ##STR196## 11.77-13.03 (4H, br, CO.sub.2 H .times. 4) 58 DMSOd.sub.6 ##STR197## 3.73 (3H, s, OCH.sub.3 (A)), 3.77 (3H, s, OCH.sub.3 (A)), 4.17 (2H, br t, J = 5.0, OCH.sub.2), 6.13 (4H, s, ##STR198## CO.sub.2 H .times. 4) 59 DMSOd.sub.6 ##STR199## ##STR200## ##STR201## 60 DMSOd.sub.6 ##STR202## ##STR203## and ArH), 7.67-8.20 (1H, m, C.sub.4H), 10.87 (2H, br s, CO.sub.2 H .times. 2) 61 DMSOd.sub.6 ##STR204## 3.78 (3H, s, OCH.sub.3 (A)), 3.82 (3H, s, OCH.sub.3 (A)), 4.20 (2H, t, J = 6.0, OCH.sub.2), 6.62-7.70 (13H, m, ##STR205## 62 DMSOd.sub.6 ##STR206## 3.57 (3H, s, OCH.sub.3 (P)), 3.70 (3H, s, OCH.sub.3 (A)), 3.73 (3H, s, OCH.sub.3 (A)), 4.10 (2H, br t, J = 5.0, ##STR207## 7.68-8.20 (1H, m, C.sub.4H), 11.37-12.83 (4H, br, CO.sub.2 H .times. 4) 63 DMSOd.sub.6 ##STR208## 3.55 (3H, s, OCH.sub.3 (P)), 3.67 (3H, s, OCH.sub.3 (A)), 3.70 (3H, s, OCH.sub.3 (A)), 3.87-4.32 (2H, m, OCH.sub.2), ##STR209## (1H, m, C.sub.4H), 10.83 (4H, br s, CO.sub.2 H .times. 4) 64 DMSOd.sub.6 ##STR210## 3.59 (3H, s, OCH.sub.3 (P)), 3.70 (3H, s, OCH.sub.3 (A)), 3.74 (3H, s, OCH.sub.3 (A)), 3.80-4.30 (2H, m, OCH.sub.2), ##STR211## (1H, m, C.sub.4H), 10.90-12.20 (4H, br, CO.sub.2 H .times. 4) 65 DMSOd.sub.6 ##STR212## 3.57 (3H, s, OCH.sub.3 (P)), 3.70 (3H, s, OCH.sub.3 (A)), 3.73 (3H, s, OCH.sub.3 (A)), 3.87-4.33 (2H, m, OCH.sub.2), ##STR213## m, C.sub.4H), 11.17-12.67 (4H, br, CO.sub.2 H .times. 4) 66 DMSOd.sub.6 ##STR214## 3.53 (3H, s, OCH.sub.3 (P)), 3.65 (2H, t, J = 5.5, CH.sub.2 OH), 3.87-4.23 (2H, m, OCH.sub.2), 6.12 (4H, s, ##STR215## 9.20-11.20 (5H, br, CO.sub.2 H .times. 4 and OH) 67 DMSOd.sub.6 ##STR216## 3.59 (3H, s, OCH.sub.3 (P)), 3.64 (3H, s, OCH.sub.3 (A)), 3.78 (6H, s, OCH.sub.3 .times. 2 (A)), 3.84-4.30 (2H, m, ##STR217## 7.80-8.10 (1H, m, C.sub.4H), 11.00-13.50 (2H, br, HCl .times. 2) 68 DMSOd.sub.6 ##STR218## 3.56 (3H, s, OCH.sub.3 (P)), 3.74 (3H, s, OCH.sub.3 (A)), 3.77 (3H, s, OCH.sub.3 (A)), 3.79 (3H, s, OCH.sub.3 (A)), ##STR219## ##STR220## ##STR221## 69 DMSOd.sub.6 ##STR222## ##STR223## ##STR224## br s, CO.sub.2 H .times. 4) 70 DMSOd.sub.6 ##STR225## 3.59 (3H, s, OCH.sub.3 (P)), 3.74 (3H, s, OCH.sub.3 (A)), 3.82 (6H, s, OCH.sub.3 .times. 2 (A)), 3.93-4.23 (2H, m, ##STR226## 7.37 (6H, m, C.sub.2H and ArH), 7.67-8.13 (1H, m, C.sub.4H), 9.50-11.50 (4H, br, CO.sub.2 H .times. 4) 71 DMSOd.sub.6 ##STR227## (3H, s, OCH.sub.3 (P)), 3.70 (6H, s, OCH.sub.3 .times. 2 (A)), 4.03 (2H, t, J = 5.0, OCH.sub.2), 6.45 (1H, d, J = 2.0, ##STR228## br s, CO.sub.2 H .times. 2) 72 DMSOd.sub.6 ##STR229## ##STR230## ##STR231## 7.70-8.10 (1H, m, C.sub.4H), 9.83-12.00 (2H, br, CO.sub.2 H .times. 2) 73 DMSOd.sub.6 ##STR232## ##STR233## m, C.sub.2H, C.sub.5H, C.sub.6H, C.sub.7H and C.sub.3 'H), 7.75 (1H, d, J = 2.5, C.sub.6 'H), 7.70-8.37 (1H, m, C.sub.4H), 8.23 (1H, dd, J = 9.0, 2.5, C.sub.4 'H), 11.30-12.50 (4H, br, CO.sub.2 H .times. 4) 74 DMSOd.sub.6 ##STR234## ##STR235## ##STR236## 7.72 (1H, d, J = 2.5, C.sub.6 'H), 7.77-8.10 (1H, m, C.sub.4H), 8.17 (1H, dd, J = 9.0, 2.5, C.sub.4 'H), 11.00-12.27 (4H, br, CO.sub.2 H .times. 4) 75 DMSOd.sub.6 ##STR237## ##STR238## 6.75-7.48 (5H, m, C.sub.2H, C.sub.5 H, C.sub.6H, C.sub.7H and C.sub.3 'H), 7.63 (1H, d, J = 2.5, C.sub.6 'H), 7.65-8.25 (2H, m, C.sub.4H and C.sub.4 'H), 10.38 (2H, br s, CO.sub.2 H .times. 2) 76 d DMSO.sub.6 ##STR239## ##STR240## 8.19 (1H, d, J = 9.0, 2.5, C.sub.4 'H), 10.50-11.92 (4H, br, CO.sub.2 H .times. 4) 77 DMSOd.sub.6 ##STR241## ##STR242## 6.80-7.42 (5H, m, C.sub.2H, C.sub.5H, C.sub.6H, C.sub.7H and C.sub.3 'H), 7.28 (5H, s, C.sub.6 H.sub.5), 7.62-8.32 (1H, m, C.sub.4H), 7.69 (1H, d, J = 2.5, C.sub.6 'H), 8.14 (1H, dd, J = 9.0, 2.5, C.sub.4 'H), 9.00-11.75 (5H, br, CO.sub.2 H .times. 4 and OH) 78 DMSOd.sub.6 ##STR243## ##STR244## m, C.sub.2H, C.sub.5H, C.sub.6H, C.sub.7H and C.sub.3 'H), 7.67-8.51 (3H, m, C.sub.4H, C.sub.4 'H and C.sub.6 'H), 7.88 (2H, d, J = 8.8, ##STR245## 79 DMSOd.sub.6 ##STR246## ##STR247## ##STR248## C.sub.4 'H), 11.64-12.51 (1H, br, HCl) 80 CDCl.sub.3 ##STR249## 3.81 (3H, s, OCH.sub.3 (A)), 3.84 (3H, s, OCH.sub.3 (A)), 3.90 (3H, s, OCH.sub.3 (P)), 4.20-4.65 (2H, m, OCH.sub.2), ##STR250## and HCl .times. 2), 7.50 (1H, d, J = 2.5, C.sub.4 'H), 7.67 (1H, d, J = 2.5, C.sub.6 'H) 81 DMSOd.sub.6 ##STR251## 3.70 (6H, s, OCH.sub.3 .times. 2 (P, A)), 3.73 (3H, s, OCH.sub.3 (A)), 3.73-4.07 (2H, m, OCH.sub.2), 6.13 (4H, s, ##STR252## CO.sub.2 H .times. 4) 82 DMSOd.sub.6 ##STR253## ##STR254## 6.63-7.32 (11H, m, C.sub.2H and ArH), 7.69-8.10 (1H, m, C.sub.4H), 11.42 (4H, s, CO.sub.2 H .times. 4) 83 DMSOd.sub.6 ##STR255## 3.67 (6H, s, OCH.sub.3 .times. 2 (P, A)), 3.70 (3H, s, OCH.sub.3 (A)), 3.93 (2H, t, J = 6.0, OCH.sub.2), 6.10 (4H, s, ##STR256## 84 DMSOd.sub.6 ##STR257## 3.70 (6H, s, OCH.sub.3 .times. 2 (P,A)), 3.73 (3H, s, OCH.sub.3 (A)), 3.97 (2H, t, J = 6.0, OCH.sub.2), 6.12 (4H, s, ##STR258## 85 DMSOd.sub.6 ##STR259## 3.63 (6H, s, OCH.sub.3 .times. 2 (P)), 3.70 (3H, s, OCH.sub.3 (A)), 3.70-4.10 (2H, m, OCH.sub.2), 3.73 (3H, s, OCH.sub.3 (A)), ##STR260## (1H, m, C.sub.4H), 10.50-12.00 (4H, br, CO.sub.2 H .times. 4) 86 CDCl.sub.3 ##STR261## ##STR262## 7.50-8.50 (1H, m, C.sub.4H), 8.00-10.00 (2H, br, NHand HCl) 87a DMSOd.sub.6 ##STR263## ##STR264## 7.50 (8H, m, C.sub.2H and ArH), 7.80-8.20 (1H, m, C.sub.4H), 9.90-11.00 (1H, br, HCl) 87b DMSOd.sub.6 ##STR265## ##STR266## ArH), 7.70-8.27 (1H, m, C.sub.4H), 9.70-10.80 (1H, br, HCl) 88 CDCl.sub.3 1.43 (6H, t, J = 7.0, N(CH.sub.2 CH.sub.3).sub.2), 2.32 (3H, s, COCH.sub.3), 3.10-3.70 (6H, m, CH.sub.2 N(CH.sub.2 CH.sub.3).sub.2), 3.9-4.7 (2H, m, OCH.sub.2 CH), 4.50-5.00 (1H, br, CH(OH)), 5.50-6.10 (1H, br, OH), 6.60-7.40 (8H, m, C.sub.2H and ArH), 7.50-8.30 (1H, m, C.sub.4H), 10.50-11.40 (1H, br, HCl) 89 DMSOd.sub.6 ##STR267## ##STR268## (1H, m, C.sub.4H), 10.90-11.50 (1H, br, HCl) 90 DMSOd.sub.6 ##STR269## ##STR270## C.sub.4H) 91 DMSOd.sub.6 ##STR271## ##STR272## (1H, m, C.sub.4H), 10.37 (2H, br s, CO.sub.2 H .times. 2) 92 DMSOd.sub.6 ##STR273## ##STR274## 6.80-7.50 (11H, m, C.sub.2H and ArH), 7.80-8.20 (1H, m, C.sub.4H), 9.20-9.83 (2H, br, CO.sub.2 H .times. 2) 93 CDCl.sub.3 ##STR275## 3.58 (3H, s, OCH.sub.3 (P)), 3.85-4.50 (2H, m, OCH.sub.2), 6.43 (1H, d, J = 2.0, C.sub.6 'H), 6.67-8.12 (12H, m, C.sub.2H and ArH), 8.13 (2H, br s, CO.sub.2 H .times. 2) 94 DMSOd.sub.6 ##STR276## 4.06 (1H, m, CHOH), 4.10-4.69 (2H, m, OCH.sub.2), 6.86-7.60 (5H, m, C.sub.2H, C.sub.5H, C.sub.6H, C.sub.7H and C.sub.3 'H), 7.71 (1H, d, J = 2.5, C.sub.6 'H), 7.83-8.49 (1H, m, C.sub.4H), 8.13 (1H, dd, J = 9.0, 2.5, C.sub.4 'H), 8.18 (3H, s, CO.sub.2 H .times. 2 and OH) 95 DMSOd.sub.6 ##STR277## 4.61 (2H, m, OCH.sub.2), 6.89-7.55 (10H, m, C.sub.2H and ArH), 7.70 (1H, d, J = 2.5, C.sub.6 'H), 7.81-8.31 (1H, m, C.sub.4H), 8.28 (1H, dd, J = 9.0, 2.5, C.sub.4 'H), 9.48 (2H, br s, CO.sub.2 H .times. 2) 96 CDCl.sub.3 1.88-2.85 (4H, m, OCH.sub.2 CH.sub.2 CH.sub.2 CO.sub.2 H), 2.20 (3H, s, COCH.sub.3), 4.10 (2H, t, J = 5.5, OCH.sub.2), 6.60-7.50 (8H, m, C.sub.2H and ArH), 7.70-8.50 (1H, m, C.sub.4H), 10.88 (1H, br s, C O.sub.2 H) 97 CDCl.sub.3 1.27 (3H, t, J = 7.0, CO.sub.2 CH.sub.2 CH.sub.3), 1.88-2.80 (4H, m, OCH.sub.2 CH.sub.2 CH.sub.2 CO.sub.2), 2.20 (3H, s, COCH.sub.3), 4.12 (2H, t, J = 6.0, OCH.sub.2), 4.18 (2H, q, J = 7.0, CO.sub.2 CH.sub.2 CH.sub.3), 6.60-7.40 (8H, m, C.sub.2H and ArH), 7.80-8.50 (1H, m, C.sub.4H) 98 CDCl.sub.3 ##STR278## (2H, q, J = 7.0, NHCH.sub.2 CH.sub.2), 3.77 (3H, s, OCH.sub.3 (A)), 3.82 (3H, s, OCH.sub.3 (A)), 4.08 (2H, t, J = 5.5, OCH.sub.2), 5.70-6.20 (1H, br, NH), 6.50-7.50 (11H, m, C.sub.2H and ArH), 7.60-8.50 (1H, m, C.sub.4H) 99 DMSOd.sub.6 ##STR279## ##STR280## ArH), 7.80-8.20 (1H, m, C.sub.4H), 10.70 (2H, br s, CO.sub.2 H .times. 2) 100 CDCl.sub.3 ##STR281## t, J = 5.5, OCH.sub.2), 6.60-7.40 (8H, m, C.sub.2H and ArH), 7.70-8.50 (1H, m, C.sub.4H)
Pharmacological Activities
Calcium antagonists have not only potentially beneficial effects in the treatment of many diseases but also serve as valuable research tools to elucidate excitation-contraction coupling in various muscle types (A. Fleckenstein, Ann. Rev. Pharmacol., 17, 149-166, 1977). Therefore, we examined the calcium-antagonistic activity of the compounds of this invention.
Pharmacological test I
The action potentials on the smooth muscles of uterus, teania coli and portal vein are dependent on calcium ion, and therefor these smooth muscle preparations are useful for screening of calcium antagonists. We measured the calcium-antagonistic activity of the compounds by the method using guinea-pig teania coli preparation.
Isolated guinea-pig teania coli was suspended in a 20 ml organ bath with Krebs solution at 32.degree. C. and bubbled with 5% carbon dioxide in oxygen. After equilibration, the muscle was washed with Ca.sup.++ -free Krebs solution, and when the muscle had relaxed to basal level, it was suspended in Ca.sup.++ -free-high-K Krebs solution.
The muscle was exposed to test compounds for 5 minutes before addition of CaCl.sub.2, and the contraction evoked by CaCl.sub.2 (3.times.10.sup.-4 M) was recorded isotonically. The calcium-antagonistic activity was represented by the concentration of test compound which elicited 50% inhibition of Ca.sup.++ -evoked contraction (IC.sub.50).
As shown in Table XI, the compounds of this invention had calcium-antagonistic activity.
Blood platelet plays an important role only in hemostasis but also in thrombosis. Platelet hyperaggregability leads to an inclease in the number of circulating platelet aggregates, which may contribute toward the development of cardiac arrythmias, cardiac arrest or myocardial infarction. These cardiovascular diseases can be prevented by inhibition of platelet aggregation. Therefor, we screened the influence of test compounds on platelet aggragation in vitro, and found that they have anti-aggregatory activity.
Pharmacological test II
Blood was obtained from an anesthetized rabbit using 0.1 volumes of 3.8% sodium citrate as anticoagulant. Platelet rich plasma (PRP) was isolated by centrifugation at 650 rpm for 10 minutes at room temperature. After preincubation of PRP (0.25 ml) with various concentrations of test compounds (14 .mu.l) for 1 minute at 37.degree. C., collagen (3 .mu.g/ml: final concentration) or ADP (3 .mu.M: final concentration) was added to induce aggregation and the aggregation profiles were monitored with RIKADENKI six-channel aggregometer. The control experiment contained saline instead of test compound.
The anti-aggregatory activity was represented by the concentration of test compound which elicited 50% inhibition of control response.
As shown in the Table XII, the compounds of this invention had anti-aggregatory activity.
TABLE XI______________________________________Calcium-antagonistic activityCompound No. IC.sub.50 [M]______________________________________23 6.6 .times. 10.sup.-733 5.2 .times. 10.sup.-763 6.4 .times. 10.sup.-767 4.7 .times. 10.sup.-7______________________________________
TABLE XII______________________________________Anti-aggregatory activityCompound No. IC.sub.50 [M]______________________________________ 8 4.6 .times. 10.sup.-621 1.3 .times. 10.sup.-622 1.1 .times. 10.sup.-629 3.2 .times. 10.sup.-654 3.1 .times. 10.sup.-655 2.0 .times. 10.sup.-695 2.7 .times. 10.sup.-6______________________________________
Toxicity test
Acute toxicity of the compounds of this invention is shown in Table XIII. (animal)
Male ddy-SLC strain rats (4 weeks of age, weighing 19-21 g) were placed in a breeding room of constant temperature and huminity (23.+-.1.degree. C., 55.+-.5%) and fed freely pellet diet and water ad. libitum for a week. Rats showing normal growth were selected for the test. (method of administration)
Test compounds are suspended in 0.5% tragacanth suspention and administered orally in a dose of 0.5 ml/20 g body weight.
TABLE XIII______________________________________Compound No. LD.sub.50 (mg/Kg)______________________________________29 >2,00063 .gtoreq.3,00067 >1,000______________________________________
The compounds can be administered either orally or parenterally. The dosage forms are tablet, capsule, granule, powder, suppository, injection, etc. The dose is adjusted depending on symptom, dosage form, etc., but usual daily dosage is 1 to 5,000 mg, preferably 10 to 1,000 mg, in one or a few divided doses.
Examples of formulation are shown below.
______________________________________Example of formulation______________________________________(a) tablet compound 8 30 mg lactose 150 mg crystalline cellulose 50 mg calcium carboxymethylcellulose 7 mg magnesium stearate 3 mg total 240 mg compound 21 50 mg lactose 120 mg crystalline cellulose 60 mg calcium carboxymethylcellulose 7 mg magnesium stearate 3 mg total 240 mg compound 22 60 mg lactose 120 mg crystalline cellulose 60 mg calcium carboxymethylcellulose 7 mg magnesium stearate 3 mg total 250 mg compound 23 40 mg lactose 150 mg crystalline cellulose 50 mg calcium carboxymethylcellulose 7 mg magnesium stearate 3 mg total 250 mg compound 33 70 mg lactose 110 mg crystalline cellulose 60 mg calcium carboxymethylcellulose 7 mg magnesium stearate 3 mg total 250 mg______________________________________
The tablets may be treated with the common film-coating and further with sugar-coating.
______________________________________(b) granule compound 63 30 mg polyvinylpyrrolidone 25 mg lactose 385 mg hydroxypropylcellulose 50 mg talc 10 mg total 500 mg compound 29 50 mg polyvinylpyrrolidone 25 mg lactose 365 mg hydroxypropylcellulose 50 mg talc 10 mg total 500 mg(c) powder compound 54 30 mg lactose 500 mg starch 440 mg colloidal silica 30 mg total 1000 mg compound 67 50 mg lactose 480 mg starch 440 mg colloidal silica 30 mg total 1000 mg(d) capsule compound 55 30 mg lactose 102 mg crystalline cellulose 56 mg colloidal silica 2 mg total 190 mg compound 95 50 mg glycerol 329.8 mg butyl p-hydroxybenzoate 0.02 mg total 380 mg______________________________________
UTILITY IN AN INDUSTRIAL FIELD
This invention offers novel compounds which are useful for therapeutic agent.

Number	Name	Date
3340266	Howe et al.	Sep 1967
3658829	Nakamura et al.	Apr 1972
3720683	Breuer et al.	Mar 1973

Number	Date	Country
0071071	Jun 1978	JPX
0179175	Nov 1982	JPX

Benzothiazoline compounds

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract

Description

Claims

Priority Claims (1)

PCT Information

US Referenced Citations (3)

Foreign Referenced Citations (2)

Non-Patent Literature Citations (2)

Entry
Cossey, Judd, and Stephens, "Some Anti-microbial Compounds in the Heteocyclic Series"-J. Chemical Society, 1965, pp. 954-973.
P. J. Palmer, R. B. Trigg, and J. V. Warrington, "Benzothiazolines as Antituberculous Agents"-Journal of Medicinal Chemistry, 1971, vol. 14, No. 3-pp. 248-251.